TCL Archive NCI advisors approved in concept the Institute’s plan to spend $24 million over five years for research on “patient navigator” programs. March 26, 2004
TCL Archive Cancer Patients Satisfied With Experience In Clinical Trials, Survey Of 2,000 Finds July 28, 2006
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
